Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker CGEM · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Oct 28, 2026 | A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients NCT07722767 · AML (Acute Myeloid Leukemia) CLN-049, Azacitidine | CGEM Cullinan Therapeutics Inc. | Phase 1 | Not yet recruiting | 90 | Sep 30, 2027 | Registry ↗ |
| Oct 28, 2026 | CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndro… NCT05143996 · Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysp… CLN-049 | CGEM Cullinan Therapeutics Inc. | Phase 1/2 | Recruiting | 275 | Dec 30, 2029 | Registry ↗ |
| Oct 26, 2026 | A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sy… NCT06613360 · SLE, SLE (Systemic Lupus) CLN-978 | CGEM Cullinan Therapeutics Inc. | Phase 1 | Recruiting | 24 | Dec 2026 | Registry ↗ |
| Oct 22, 2026 | A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL) NCT05879744 · NHL, NHL, Relapsed, Adult CLN-978 | CGEM Cullinan Therapeutics Inc. | Phase 1 | Terminated | 3 | Jun 1, 2024 | Registry ↗ |
| Oct 20, 2026 | A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rh… NCT06994143 · Rheumatoid Arthritis (RA CLN-978 | CGEM Cullinan Therapeutics Inc. | Phase 1 | Recruiting | 37 | Dec 30, 2027 | Registry ↗ |
| Aug 11, 2026 | A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sj… NCT07041099 · Sjögren, Sjogren Disease CLN-978 | CGEM Cullinan Therapeutics Inc. | Phase 1 | Recruiting | 36 | Mar 15, 2028 | Registry ↗ |
| Jul 31, 2026 | A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA NCT07738822 · Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic An… Velinotamig specified dose on specified days. | CGEM Cullinan Therapeutics Inc. | Phase 1/2 | Not yet recruiting | 72 | Jan 2029 | Registry ↗ |
| Jun 18, 2026 | CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors NCT06035744 · Advanced Solid Tumor CLN-617, Pembrolizumab | CGEM Cullinan Therapeutics Inc. | Phase 1 | Terminated | 23 | Jun 16, 2026 | Registry ↗ |
| Jun 17, 2026 | A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer NCT04036682 · Non Small Cell Lung Cancer, EGFR Exon 20 Mutation CLN-081 | CGEM Cullinan Therapeutics Inc. | Phase 1/2 | Active, not recruiting | 284 | Oct 13, 2025 | Registry ↗ |
| Nov 24, 2025 | A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors NCT05117476 · Advanced Solid Tumor, NSCLC CLN-619, Pembrolizumab | CGEM Cullinan Therapeutics Inc. | Phase 1 | Active, not recruiting | 440 | Mar 2026 | Registry ↗ |
| Sep 18, 2025 | A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myel… NCT06381141 · Multiple Myeloma CLN-619 | CGEM Cullinan Therapeutics Inc. | Phase 1 | Active, not recruiting | 30 | Sep 2026 | Registry ↗ |
| Aug 15, 2023 | Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carci… NCT03682055 · Nasopharyngeal Carcinoma, Nasopharyngeal Cancer VK-2019 | CGEM Cullinan Therapeutics Inc. | Phase 1/2 | Terminated | 14 | Jun 23, 2020 | Registry ↗ |
12 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:59 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances